

## **Aurora Spine Corporation Issued Patent by USPTO For Its Interlaminar Single Implant Technology For Motion Preservation or Fusion**

CARLSBAD, Calif., June 13, 2022 — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of United States Patent No: 11,331,199 entitled “Spinal Implant for Motion Preservation or Fusion.” This patent covers Aurora’s ZIPFlex™ Technology for a minimally invasive posterior interlaminar implant for motion preservation that could be adapted into a fusion or non-fusion device while implanted in a patient via a small modular attachment.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

This new patent covers interlaminar motion-preserving and fusion implants in one device that could treat lumbar spinal degenerative diseases, such as spinal stenosis. Over the last 50 years, spinal fusion has become the gold standard for treating several degenerative spinal disorders. Motion preservation surgeries are also popular since they avoid total fusion. A ZIPFlex Technology-based implant could be implanted as a motion preservation device and months or years later could be easily converted from motion preservation device to a fusion implant via a minor keyhole procedure by adding a blocker element at the center of the main body. Patented features of ZIPFlex™ include individually adjustable anchors to prevent implant migration and unnecessary bone removal to fit the implant. Aurora’s ZIPFlex is the first technology to offer an all-in-one approach to providing viable options for treating patients with back pain.

“Some of the difficulty with traditional spinal fusion systems is that stabilization or additional fusion may be required intraoperatively, particularly to protect adjacent levels after spinal surgery and to protect degenerative segments following decompressive surgery,” said Steven Falowski, M.D., Director of Functional Neurosurgery at Argires-Marotti Neurosurgical Associates of Lancaster, PA. “Aurora received the ZIPFlex patent, with its proprietary Modular In-Situ Fusion Block, a device that provides the surgeon with the ability to determine whether to stabilize or fuse a patient intraoperatively during the procedure or to allow motion preservation. This is a major step forward in delivering the best options long term for your patients.”

Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, “As our IP portfolio continues to grow, so does the positive impact we can make for our physician customers and their patients. With this latest patent grant from the USPTO, we have further strengthened our value proposition and the depth and breadth of our portfolio of minimally invasive interlaminar devices.”

Mr. Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, added, “We are excited to receive this patent covering the technology of our proposed ZIPFlex device. Aurora’s motto, “Simplifying the Complex” is the focus of every product we create. The “two-in-one” ZIPFlex device patent is another example of how the company is working to build upon its IP and offer our customers highly technical products that contain an ‘ease of use’ element.”

## **About Aurora Spine**

Aurora Spine focuses on bringing new solutions to the spinal implant market through innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at [www.aurora-spine.com](http://www.aurora-spine.com) or [www.aurorapaincare.com](http://www.aurorapaincare.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

## **Forward-Looking Statements**

*This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any information that expresses or involves discussions as to expectations, beliefs, plans, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release, and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.*

## **Contact:**

Aurora Spine Corporation

Trent Northcutt  
President and Chief Executive Officer

(760) 424-2004

Chad Clouse  
Chief Financial Officer  
(760) 424-2004  
[www.aurora-spine.com](http://www.aurora-spine.com)

Adam Lowensteiner  
LYTHAM PARTNERS, LLC  
Phoenix | New York  
Telephone: 646-829-9700  
[asapf@lythampartners.com](mailto:asapf@lythampartners.com)

